Sutro biopharma

Key events shows relevant news articles on days with large price movements. Gossamer Bio Inc.

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways. Many thanks to our Sutro team for their continuous efforts in placing our patients first. We appreciate and value all the work you have done! To read the report, click the link. Dedicated to our Patients and Changing the Future of Oncology.

Sutro biopharma

Skip to main content. Sutro Biopharma, Inc. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. Vaxcyte, Inc. Sutro or the Company NASDAQ: STRO , a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ADCs , today reported its financial results for the third quarter of , its recent business highlights, and a preview of select anticipated milestones. Sutro or the Company NASDAQ: STRO , a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ADCs , today reported its financial results for the second quarter of , its recent business highlights, and a preview of select anticipated milestones. PT in New York City. Sutro or the Company NASDAQ: STRO , a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ADCs , today reported its financial results for the first quarter of , its recent business highlights, and a preview of select anticipated milestones. Sutro Biopharma Appoints Dr. First 1 2 3 4 5 Next Last.

First 1 2 3 4 5 Next Last.

Sutro Biopharma, Inc. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in STRO is an ADC targeting folate receptor alpha , a cell-surface protein highly expressed in gynecological cancers. As of [update] Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine -based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal. In July , Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. In , Sutro and Celgene announced they had refocused their immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen BCMA.

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways. Many thanks to our Sutro team for their continuous efforts in placing our patients first. We appreciate and value all the work you have done! To read the report, click the link. Dedicated to our Patients and Changing the Future of Oncology. Learn More. Sutro Biopharma, Inc. Our Technology.

Sutro biopharma

Sutro Biopharma, Inc. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in STRO is an ADC targeting folate receptor alpha , a cell-surface protein highly expressed in gynecological cancers. As of [update] Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine -based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal. In July , Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. In , Sutro and Celgene announced they had refocused their immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen BCMA.

Jack skellington onesie

Gossamer Bio Inc. Return on capital. Learn more. As of [update] Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine -based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal. Korn Ferry. Cash from operations. OVID 0. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. In , Sutro and Celgene announced they had refocused their immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen BCMA. Sutro Biopharma, Inc. The total amount of assets owned by a company. Ovid Therapeutics Inc. Sutro or the Company NASDAQ: STRO , a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ADCs , today reported its financial results for the second quarter of , its recent business highlights, and a preview of select anticipated milestones. Earnings per share. Net change in cash The amount by which a company's cash balance increases or decreases in an accounting period.

.

First 1 2 3 4 5 Next Last. Earnings before interest, taxes, depreciation, and amortization, is a measure of a company's overall financial performance and is used as an alternative to net income in some circumstances. The total amount of income generated by the sale of goods or services related to the company's primary operations. Sutro or the Company NASDAQ: STRO , a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ADCs , today reported its financial results for the first quarter of , its recent business highlights, and a preview of select anticipated milestones. Previous close. About Us. KZR 0. Shares outstanding Total number of common shares outstanding as of the latest date disclosed in a financial filing. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Toggle limited content width. To read the report, click the link. PT in New York City. Biotechnology and Bioengineering. Price to book. Market cap.